Navigation Links
Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Date:5/23/2013

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML.  This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.

"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging.  Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics. 

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug.  Its pipeline of validated targets treat diseases therapeutically and prophylactically.  By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
2. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
3. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
4. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Novelos Therapeutics Provides Product Pipeline Update
10. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
11. Mast Therapeutics Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2
... Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... (Nasdaq: MGRM ) today announced five posters to be,presented at the 30th ... - 16, 2007. Following are details for,each embargoed session:, -- Friday, ...
... Tainted Research Grant Applications Must Be Rejected, Consumer,Advocates ... More apparent,conflict of interest violations in applications for ... were revealed today and the,Foundation for Taxpayer and ... to be rejected., The latest improprieties were ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3New Conflict of Interest Violations Revealed at California Stem Cell Institute 2New Conflict of Interest Violations Revealed at California Stem Cell Institute 3
(Date:7/13/2014)... Advanced boilers are preferred over conventional ... fossil fuels, produce high-capacity power, emit fewer pollutants, ... warming and climate change concerns, many countries have ... emissions and pollutants coming from fossilfuel-based power plants.North ... advance boilers market., The global power rental market ...
(Date:7/13/2014)... 2014 MarketsandMarkets recently conducted a ... 3D Scanning; 3D rendering; Layout and Animation; Image ... - 2018)”, which analyzes and studies the major ... Western Europe, Eastern Europe, Middle East and Africa, ... the competitive landscape of the 3D imaging market, ...
(Date:7/13/2014)... 13, 2014 The Pearland, Texas location of ... age from four months to 12 years of age that ... to birthday parties and Summer Camps, is now under new ... of Pearland after spending over six years at The ... Gym Director. , Berry has over ten years of ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace ... Recently, the company has announced its new selection of ... all these outfits are available at discounted prices (from ... supplier is now offering similar discounts for many other ... many other designs for sale, including flower girl dresses, ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2
... , RANCHO CORDOVA, Calif., Dec. 10 ThermoGenesis Corp. ... for processing and storing adult stem cells, said today that ... healthcare industry experience, has been named to the Company,s board ... directors to six. , Moore is currently associated with several ...
... , , EXTON, Pa., Dec. 10 Kensey Nash ... directors has approved a stock repurchase. The new program allows ... its issued and outstanding shares of Common Stock and has no ... its available cash. , Kensey Nash Corporation plans to repurchase its ...
... an early sign of Parkinson,s disease, according to neurologists ... to slow further brain cell damage until strategies to ... an age-related disorder involving loss of certain types of ... speech. "The disease is currently diagnosed by ...
... ... and challenges of leveraging communications technologies before, during and after crises , ... Washington, DC and London, ... released a landmark publication today, Human Rights Day, on the use of communications ...
... ST. LOUIS, Dec. 10 Centene Corporation (NYSE: ... 2010 financial guidance at approximately 6:00 AM (Eastern Time) on ... at approximately 8:30 AM (Eastern Time) to discuss the details ... Officer, and William N. Scheffel, Executive Vice President, Chief Financial ...
... PARK CITY, Utah, Dec. 10 Nutraceutical International Corporation (Nasdaq: ... and year ended September 30, 2009. Net sales for the ... for the same quarter of fiscal 2008. For the fourth ... diluted earnings per share, compared to net income of $1.5 million, ...
Cached Medicine News:Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4Health News:Kensey Nash Announces 400,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 400,000 Share Stock Repurchase Program 3Health News:Irregular arm swing may point to Parkinson's disease 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 3Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 4Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 2Health News:Nutraceutical Reports Fiscal 2009 Year End Results 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 4Health News:Nutraceutical Reports Fiscal 2009 Year End Results 5Health News:Nutraceutical Reports Fiscal 2009 Year End Results 6Health News:Nutraceutical Reports Fiscal 2009 Year End Results 7Health News:Nutraceutical Reports Fiscal 2009 Year End Results 8
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
Medicine Products: